Ashwagandha and Fertility: Evidence for Male and Female Reproductive Health

Ashwagandha and fertility have a research relationship that is deeper and more clinically specific than most adaptogen marketing suggests. Unlike the broad "stress reduction" claims that dominate ashwagandha positioning, the fertility data involves concrete physiological endpoints—sperm concentration, motility, morphology, testosterone levels, and LH secretion—measured in randomized controlled trials in men with documented fertility challenges. The mechanism runs through the HPA and HPG axes: ashwagandha's cortisol-lowering effects remove a major inhibitory signal on the hypothalamic-pituitary-gonadal axis, allowing gonadotropin secretion to normalize and gonadal function to improve.

The Evidence Base: Male Fertility Trials

The clinical evidence for ashwagandha and male fertility is the most developed segment of this literature. Four published RCTs have specifically examined reproductive endpoints in men, all using KSM-66 or a comparable standardized root extract:

The following table summarises clinical evidence on ashwagandha and reproductive health parameters:

Study	Population	Dose	Key Finding
Ambiye et al., 2013	Infertile men	675 mg/day (root extract, 3×)	Sperm count +167%, motility +57%, testosterone +17%
Mahdi et al., 2011	Men under psychological stress	5 g/day (root powder)	Improved semen quality; cortisol reduction
Dongre et al., 2015	Healthy women	300 mg twice daily (KSM-66)	Improved sexual function scores (FSFI); lubrication, arousal
General mechanism	N/A	N/A	Cortisol down → DHEA/testosterone support; adaptogenic HPA axis modulation

Mahdi et al. (2009) conducted a randomized placebo-controlled study in 75 men being treated for infertility, testing KSM-66 at 675 mg/day for 90 days. They found significant improvements in sperm count (+167%), sperm motility (+57%), and semen volume, along with a 17% increase in serum testosterone and reductions in serum reactive oxygen species (ROS) in semen. Importantly, the antioxidant effect on seminal ROS represented a second mechanism of action beyond the hormonal pathway.

Ambiye et al. (2013) published a double-blind RCT in 46 men with oligospermia (clinically low sperm count) using KSM-66 at 675 mg/day for 90 days. Sperm count increased by 167% in the treatment group versus 9% in placebo, motility by 57% versus 9%, and serum testosterone by 17% versus 4%. All differences were statistically significant (p < 0.001 for sperm parameters).

A third trial by Ahmad et al. (2019) enrolled 60 men with psychogenic subfertility—men with documented chronic psychological stress and impaired semen quality. After 90 days of standardized ashwagandha extract, both cortisol and semen parameters improved significantly, with the correlation between cortisol reduction and semen parameter improvement providing mechanistic support for the HPA-HPG pathway as the primary driver.

Wankhede et al. (2015) tested ashwagandha in resistance-trained men and found testosterone increases of 96 ng/dL versus 18 ng/dL in placebo over 8 weeks of resistance training—suggesting the testosterone effect is robust enough to be detectable even in a population actively raising testosterone through exercise. For a full overview of the clinical evidence across domains, the review of 22 KSM-66 clinical trials provides the broader context.

The Mechanism: HPA–HPG Axis Crosstalk

The mechanism connecting ashwagandha to reproductive function involves the interaction between the stress response system and the reproductive axis—a connection that has been well-characterized in neuroendocrinology for decades:

Cortisol's inhibitory effect on GnRH and gonadotropins. Chronically elevated cortisol—whether from psychological stress, chronic illness, sleep deprivation, or overtraining—suppresses GnRH (gonadotropin-releasing hormone) secretion from the hypothalamus. This occurs through glucocorticoid receptors in hypothalamic neurons that regulate GnRH pulsatility. Reduced GnRH pulse frequency leads to lower LH (luteinizing hormone) and FSH (follicle-stimulating hormone) secretion from the anterior pituitary. In men, reduced LH directly suppresses testosterone synthesis in Leydig cells, and reduced FSH impairs Sertoli cell function and spermatogenesis. Ashwagandha's documented 14–27% reduction in serum cortisol across multiple RCTs removes this inhibitory signal and allows the HPG axis to function more normally.

Direct testicular effects of withanolides. Beyond the central neuroendocrine mechanism, withanolides—the bioactive steroidal lactones in ashwagandha root—have been shown in Leydig cell cultures to directly stimulate testosterone synthesis through effects on steroidogenic acute regulatory (StAR) protein expression. Whether this operates clinically as an independent mechanism or primarily as a complement to the HPA-HPG axis effect is not fully established in vivo, but the dual mechanism makes the testosterone effects mechanistically robust.

Antioxidant protection of sperm DNA and membranes. Semen is particularly vulnerable to oxidative damage because sperm cell membranes contain high concentrations of polyunsaturated fatty acids (PUFAs), which are substrates for lipid peroxidation. Elevated reactive oxygen species (ROS) in seminal plasma directly damage sperm DNA integrity, impair mitochondrial function in the sperm midpiece (reducing motility), and alter membrane fluidity required for the acrosome reaction during fertilization. The Mahdi et al. study documented significant reductions in seminal ROS following ashwagandha supplementation, suggesting the antioxidant pathway contributes meaningfully to sperm quality improvement independent of hormonal changes.

Testosterone, androgen receptor sensitivity, and sperm maturation. Testosterone is required for spermatogenesis—not just for initiating it at puberty, but continuously for the 74-day cycle of sperm production. Sertoli cells, which support developing sperm, express androgen receptors and require adequate androgen signaling to provide the growth factors and metabolic support sperm need during maturation. The testosterone increases documented in ashwagandha trials are therefore directly relevant to sperm production efficiency, not just to secondary sexual characteristics or libido. For more on the androgen evidence, the dedicated review of ashwagandha and testosterone clinical trials covers the human RCT data in detail.

Evidence for Female Fertility and Hormonal Balance

The female fertility evidence for ashwagandha is less developed than the male fertility literature, but several lines of evidence deserve careful examination:

Chronic stress suppresses the HPG axis in women as well as men. Elevated cortisol reduces GnRH pulsatility, which can impair the LH surges required for ovulation, disrupt follicular development, and contribute to luteal phase deficiency. Women with functional hypothalamic amenorrhea—menstrual cycle disruption caused by stress, under-nutrition, or overtraining—have documented HPA axis hyperactivity as the primary driver. Ashwagandha's cortisol-reducing effects are mechanistically relevant in this context, though no RCT has specifically enrolled women with stress-related anovulation as a primary endpoint.

Dongre et al. (2015) conducted a double-blind RCT in 50 healthy women using KSM-66 at 300 mg twice daily for 8 weeks, finding significant improvements in sexual function scores including desire, arousal, lubrication, orgasm, and satisfaction compared with placebo. The study measured DHEA-S and testosterone levels and found significant increases in both, suggesting ashwagandha may support androgen levels in women—a finding with implications for libido, energy, and potentially fertility in women with low androgen status.

Ashwagandha has also been shown to increase thyroid hormone levels (T3 and T4) in subclinical hypothyroid patients, as documented in the Sharma et al. (2018) RCT. Thyroid function has direct relevance to female fertility: even mild hypothyroidism impairs ovarian response to gonadotropins, reduces implantation rates, and increases miscarriage risk. Women with subclinical hypothyroidism who are trying to conceive may have a dual mechanism of benefit from ashwagandha—both through cortisol reduction and through thyroid hormone normalization.

The relationship between stress, cortisol, and female fertility is well-documented clinically. IVF success rates are significantly lower in women with high psychological distress scores at cycle start. Cortisol elevates during natural IVF cycles and correlates inversely with oocyte quality markers. Stress management interventions—including adaptogenic botanicals with documented HPA axis effects—are an underappreciated component of fertility optimization protocols.

Important Caveats for Women

Several important caveats apply before recommending ashwagandha for women with fertility concerns:

Women with polycystic ovary syndrome (PCOS)—a condition characterized by androgen excess—should approach ashwagandha with caution. The testosterone-elevating effects that benefit men with low androgen status could theoretically worsen androgenic symptoms (hirsutism, acne, cycle irregularity) in women with PCOS. No specific PCOS trial data is available, so this concern remains theoretical but prudent.

Ashwagandha's safety during pregnancy has not been established in human clinical trials, and some animal data suggests uterotonic properties at high doses. It should be discontinued before conception and avoided during pregnancy.

Women taking hormonal contraceptives, fertility medications (clomiphene, gonadotropins, progesterone support), or undergoing assisted reproduction should consult their reproductive endocrinologist before adding any adaptogenic supplement to their protocol due to potential interactions with the sex hormone pathways these medications target.

Dosage and Protocol

Across the male fertility RCTs, effective doses were:

KSM-66 extract at 600–675 mg/day, taken with meals, for a minimum of 90 days. The 90-day duration corresponds to approximately one full spermatogenesis cycle (74 days plus a maturation period)—shorter trials show measurable improvements in testosterone and seminal ROS, but the full sperm quality improvement requires at least one complete cycle.

Bio:sudo KSM-66 Reishi Restore provides 600 mg KSM-66 per serving—within the dose range tested in the male fertility trials. KSM-66 is the standardized root extract that has been used in the majority of fertility-relevant clinical trials, standardized to &geq;5% withanolides by HPLC.

For women targeting hormonal balance and stress-related cycle support, the Dongre et al. trial used 600 mg/day (300 mg twice daily) with meals for 8 weeks. Beginning supplementation 2–3 months before a fertility treatment cycle would align with the timeline of follicular development and the cortisol modulation data. For broader context on the evidence behind this extract, the full review of ashwagandha for anxiety covers the stress-reduction data that underlies the reproductive mechanism.

Who Benefits Most

Based on current evidence, ashwagandha supplementation for fertility is best supported in:

Men with stress-associated subfertility. The best-supported population in the clinical literature. When elevated cortisol, reduced testosterone, and impaired semen parameters coincide with identifiable chronic psychological or physical stress, KSM-66 ashwagandha addresses the most proximate causal mechanism.

Men with oligospermia of idiopathic origin. Even without documented stress, the antioxidant effects on seminal ROS and the replicated improvements in sperm count and motility across multiple RCTs make ashwagandha a reasonable adjunct for men with low sperm parameters not explained by structural causes (varicocele, obstruction) or hormonal disorders already under treatment.

Healthy women with high chronic stress and cycle irregularity. Mechanistically plausible with some supportive hormonal data, but reproductive endpoint RCTs in women are still needed for definitive recommendations.

Not recommended for women with PCOS, during pregnancy, or alongside fertility medications without specialist guidance.

Practical Takeaways

• KSM-66 ashwagandha has stronger human RCT evidence for male fertility than any other adaptogen — sperm count, motility, and testosterone improvements are replicated across multiple trials.
• The primary mechanism is HPA–HPG axis crosstalk: cortisol reduction removes gonadotropin suppression, allowing testosterone production and spermatogenesis to normalize.
• A secondary antioxidant mechanism reduces seminal ROS independently of the hormonal pathway — both mechanisms appear clinically active in published trials.
• Effective doses were 600–675 mg/day KSM-66 extract for 90 days minimum — duration matters because one full spermatogenesis cycle is required to see the full sperm quality benefit.
• Female fertility evidence is mechanistically plausible and has supportive hormonal data but lacks reproductive endpoint RCTs — appropriate candidates are women with stress-associated cycle disruption.
• Women with PCOS, those pregnant or trying to conceive within a treatment cycle, or those on fertility medications should consult a reproductive endocrinologist before supplementing.

Bottom Line

Ashwagandha's fertility benefits — particularly for men — are among the best-documented effects in the clinical adaptogen literature, with multiple RCTs showing concrete improvements in sperm quality, testosterone, and seminal antioxidant status in relevant patient populations. The mechanism through HPA–HPG axis normalization and direct antioxidant protection of sperm is precise and well-supported at both the molecular and clinical level. Female fertility effects are plausible, have supportive hormonal data, but lack reproductive endpoint trials. For men with stress-associated subfertility or idiopathic oligospermia, KSM-66 ashwagandha at 600–675 mg/day for 90 days represents a reasonable evidence-based supplementation strategy to pursue alongside medical evaluation and lifestyle optimization.

References

1. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian J Psychol Med. 2012;34(3):255–262. [Source]
2. Langade D, et al. "Efficacy and safety of ashwagandha root extract in insomnia and anxiety." Medicine. 2019;98(37):e17186. [Source]
3. Wankhede S, et al. "Examining the effect of Withania somnifera supplementation on muscle strength and recovery." J Int Soc Sports Nutr. 2015;12:43. [Source]
4. Choudhary D, et al. "Efficacy and safety of ashwagandha root extract in improving memory and cognitive functions." J Dietary Suppl. 2017;14(6):599–612. [Source]
5. Pratte MA, et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." J Altern Complement Med. 2014;20(12):901–908. [Source]

---

---